At a $48M post-money valuation, to scale mindRx — the only end-to-end medication adherence ecosystem — combining smart hardware, mobile software, enterprise analytics and pet care — across clinical trials, hospitals, hospice, veterinary, and insurance-reimbursed home health.
The Smart Cap records medication access in real time. The app keeps the patient on track. The dashboard turns that data into adherence, compliance and outcome insight for the organization. Here is what you would be investing in, from the cap up.
The hardware. A patent-pending cap with LED indicators and push-detect sensors that records medication access in real time, so every event is captured at the bottle, not recalled later.
The patient's side. Reminders, tracking and engagement for the patient, synced straight from the cap — so adherence is measured, never self-reported.
The enterprise side. Real-time adherence monitoring, compliance reporting and outcome insights for clinical trials, hospitals, hospice, veterinary, and insurance-reimbursed home health.
The same compliant platform extended to pet medication — monthly flea, tick and heartworm treatments tracked the way human doses are.
Hardware alone is not a platform. Software alone is not adherence. mindRx delivers both.
Sensor-verified, never self-reported.The full opportunity, the product, the market and the round.
The Series A data rooms, as kept in the mindRx cap table. The rooms are listed here; the files are locked until your access is approved.
View-only access after sign-in, confirming your details and signing the data room confidentiality agreement, approved by mindRx.
Regulation D 506(c) is open now to verified accredited investors — complete identity verification, confirm your accredited status, and fund by wire or ACH. Regulation CF, open to all investors, is coming soon through our broker-dealer partner.
mindRx Adherence, Inc., a Delaware corporation · 1529 Beall Street, Unit C, Houston, TX 77008.
This page is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any security. Any offering is made only by means of the official offering materials, which contain complete information about the offering, including its terms and the associated risks. The Regulation D 506(c) offering is open only to verified accredited investors. Investing in early-stage companies involves a high degree of risk, including the possible total loss of your investment, and the securities are illiquid and may not be transferable. Statements about future plans or performance are forward-looking and are not guarantees of future results. Prospective investors should read the offering materials and the associated risk factors in full, and consult their own legal, tax and financial advisers, before investing.